Australia’s medicines regulator, the Therapeutic Goods Administration, has approved Swiss pharma firm Roche’s (ROG: SIX) application to market Ocrevus (ocrelizumab) as a treatment for multiple sclerosis.
It’s the second regulatory approval for Roche in two indications: relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Approval in these indications in the USA, given in March, sent the company’s share price climbing as investors considered a potential $3 billion revenue boost for the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze